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  Abstract 
Sarcoidosis is a systemic disease that has ocular manifestations. For many 
patients there is a long course of treatment both topical and systemic.  This 
article describes sarcoidosis both systemic and ocular and some of the 
treatment modalities used. 
Introduction 
Sarcoidosis is a condition that has both systemic and ocular manifestations.  Due to 
the nature of the symptoms it can have implications for a patient’s quality of life due 
to the chronicity of the disease (Cox, Brown & Judson, 2004).  This paper discussed 
the general characteristics of sarcoidosis and goes on to consider the ophthalmic 
manifestations and in particular, uveitis and sarcoidosis 
 
What is Sarcoidosis? 
Sarcoidosis is a systemic disease characterised by granulomatous inflammation with 
the formation of noncaseating granulomas that has both systemic and ocular 
manifestations. 
Granuloma 
A granuloma is a term used loosely to refer to mean a small nodule. Pathologically 
however, a granuloma is an organised (in a tight, ball like formation) collection of 
macrophages (immune cells). It may also contain lymphocytes, neutrophils, 
eosinophils, multinucleated giant cells, fibroblasts and collagen. Granulomas form in 
response to antigens that are resistant to inflammatory cells such as neutrophils and 
eosinophils. Often, granulomas form in response to an infecting pathogen or other 
substance foreign to the body. Often though, as in sarcoidosis, the antigen is 
unknown. Granulomas may have necrosis within them and these usually have an 
infective cause. If the granuloma appears to be filled with a ‘cheese like’ substance, 
this type of necrosis is known as caseation (turning to cheese). Granulomas found in 
sarcoidosis are non necrotising, non caseating and are often surrounded by bands of 
fibrosis. They can resolve spontaneously or with scarring, as in pulmonary fibrosis 
(Adams, 1976, Iannuzzi, Rybicki, Teirstein, 2007). 
It can clinically manifest either in isolation or conjointly in any number of organs 
including lungs, skin, heart, liver, muscles, joints and the eye.  It is thought there is 
some pulmonary involvement in all patients with sarcoidosis with between 25-50% 
developing ocular symptoms either in isolation or conjointly (Kawagoe and 
Mizuki,2011).   There are also ethnic differences in presentation of sarcoidosis with 
African Americans more likely to present with Hilar Lymphadenopathy whilst 
Japanese are more likely to present with ocular sarcoidosis (Margolis and Lowder, 
2007). 
The cause of sarcoidosis is unknown but airborne particulates, viral or mycobacteria 
pathogens and occupational exposures have been raised as potential 
triggers(Margolis & Lowder, 2007).  Genetic factors may also contribute to the 
susceptibility to the development of sarcoidosis due to familial clustering and 
predominance in some racial groups (Margolis & Lowder, 2007).  There is a higher 
incidence in African Americans than in European and it is less common in Asians.  
The disease can present at any age but it is more common between the ages of 20-
50 years(Tachibana et al, 2010).   .  Females have a slightly higher predominance 
than males (Lodha, Sanchez & Prystowsky). 
Sign and symptoms 
The symptoms of sarcoidosis are varied and dependent on the primary site of 
inflammation.  Many symptoms though are non specific and can be attributed to 
other conditions and it is often a process of elimination that leads to diagnosis 
particularly if no familial links are apparent.  Patients can present in a myriad of 
different ways due to the number of systems that can be affected by the condition. 
Presenting symptoms may include; encephalopathy, vasculopathy, seizure and 
ataxia (Phillips & Eggenberger, 2010), myalgia and muscle weakness, or acute 
arthritis. Other presenting features might be weight loss and fever, pericarditis,  heart 
block, valvular disease and generalised systemic vascularitis, jaundice,  ascites and  
portal hypertension (Abril & Cohen,2003). Alternatively, patients may present with flu 
like symptoms of fevers, night chills and chronic cough.  Many of these signs and 
symptoms are not always associated with the initial presentation of ocular 
sarcoidosis. 
 
Systemic sites of Sarcoidosis 
Almost all organs in the human body can be affected by sarcoidosis.  Respiratory 
involvement is suspected in up to 90% of patients diagnosed with sarcoidosis (Abril 
&Cohen, 2003), and is characterised by hilar lymphadenopathy seen on Chest Xray 
or high resolution CT.  Hilar lymphadenopathy may not require treatment if there are 
no other sites of inflammation identified. The use of steroids to treat respiratory 
sarcoidosis is the same as treatment for other sites of inflammation so it is often a 
multi speciality decision to treat (Papadia, Herbort & Mochizuki, 2010). 
Neurosarcoidosis  has been called the ‘great mimicker’ as those affected can 
present with non specific and variable symptoms.   However, cranial neuropathy is 
the most frequent neurological manifestation in approximately 50-70% of patients 
with neurosarcoidosis.  The facial nerve and optic nerve are most commonly affected 
(Phillips & Eggenberger, 2010). 
Cutaneous Sarcoid can manifest itself in different forms.  It is often confirmed by 
biopsy of suspect skin lesions confirming the presence of granulomatous 
inflammation in the dermis.   
Erythema nodosum may be a presenting feature of sarcoidosis but is present with 
other apparent disease manifestations such as  arthritis, oedema and low grade 
fevers(Lodha, Sanchez & Prystowsky, 2009) . 
The skeletal system can also be affected.  Bone or osseous involvement can be 
involving the hands and feet and is usually associated with long standing chronic 
sarcoidosis.  The main joints involved are usually the ankles with the next most 
common the knees, wrists and elbows.  Joint involvement can lead to acute arthritis 
but in chronic sarcoidosis, chronic arthritis is more common (Abril & Cohen, 2004). 
Other sites are muscles or myopathy, kidney involvement can cause 
hypercalcaemia, cardiac symptoms vary from heart block to generalise systemic 
vascularitis  while liver involvement can cause jaundice, ascites and portal 
hypertension (Abril & Cohen,2004). 
 
Ocular Sarcoidosis 
Estimates of ocular involvement vary between 8-89% (depending on author and 
ethnicity of the study group as highlighted ealier and by Baughman et al 2001, 
Nakagawa et al 1978).  Sarcoid granulomas can affect any part of the eye and visual 
system. 
Ocular sarcoidosis presents in many guises and generally develops into a chronic 
condition in many patients resulting in long term attendance at  the eye clinic.  The 
most common form of uveitis is a bilateral granulomatous uveitis which is 
characterised by the presence of ‘mutton fat ‘keratic precipitates (KPs)..  There may 
also be inflammatory nodules (accummulations of inflammatory cells) on the 
pupillary border (known as Koeppe nodules)_ or on the iris surface (known as 
Busacca nodules) that are indicative of a granulomatous inflammation (Papadia et al, 
2010). 
However, other parts of the anterior segment can also be affected with infiltration of 
the periorbital or lacrimal tissue which  may result in keratoconjunctivitis sicca 
.Granulomas in the angle of the anterior chamber can occur leading to a high 
intraocular pressure with a small proportion of  patients requiring glaucoma drainage 
surgery. 
The posterior segment is also affected with the most common signs being 
‘snowballs’, collections of inflammatory cells in the vitreous. There can also be 
peripheral chorioretinal granulomas as seen below as well as sheathing of the retinal 
veins and periphebitis.  Cystoid macula oedema is also a known complication of 
sarcoid uveitis.  Many of these posterior complications are sight threatening and 
require urgent treatment (Papadia et al, 2010). 
  
Diagnostic tests for Ocular sarcoidosis 
A patient presenting to eye clinic with a bilateral uveitis, of unknown cause is always 
sent for screening tests.  These screening tests are a combination of radiographic 
and blood tests.  A chest x-ray is also done to identify the possibility of pulmonary 
involvement as the presence of bilateral hilar lymphadenopathy is a classic sign of 
sarcoidosis.  Around 90% of patients with sarcoid have hilar lymphadenopathy 
(Abril& Cohen, 2003).  However, if the chest x-ray is normal it may be necessary to 
do a high resolution CT scan to aid diagnosis due to the high incidence of lung 
involvement with those diagnosed with the disease (Papadia et al, 2010). 
Blood investigations include testing for a rise in Angiotension Converting Enzyme 
(ACE) and Lysosyme are undertaken as these substances are produced by sarcoid 
granulomas and therefore aid in the  diagnosis of sarcoidosis.  However, if a patient 
is on ACE inhibitors an elevated Lysozyme level may be more diagnostic (Papidia et 
al, 2010). 
Biopsy of granulomas is an ideal way to definitively diagnose sarcoidosis but  the site 
of the sarcoid determines if biopsy is possible or appropriate.  The presence of 
granulomatous inflammation in the biopsy tissue is a positive diagnosis of 
sarcoidosis (Papadia et al, 2010) 
Differential Diagnosis 
Uveitis is not solely a disease associated with sarcoidosis and therefore it is 
essential to exclude other ocular causes and systemic investigations are required to 
determine a diagnosis of sarcoidosis.  Investigations can range from simple blood 
tests to Magnetic Resonance Imaging (MRI)scans in order to diagnose sarcoidosis. 
Tuberculosis is the most important alternative diagnosis to determine.  This has 
become easier now with a blood test ‘Quantiferon TB Gold’ identifying gamma-
interferon release (Papadia et al, 2010). 
Choroidal Granulomas 
Vogt-Koyanagi-Harada (VKH) Disease is more common in Asians, Hispanics and 
Amerindians.  Although this can present with granulomatous signs, it can be 
distinguished from ocular sarcoidosis with the presence of a ‘sunset glow’ 
fundus.(Papadia, et al, 2010). 
Herpetic uveitis is usually unilateral whereas most sarcoid uveitis is bilateral.  The 
clinical picture is also different especially the presence of iris atrophy demonstrated 
on slit lamp by transillumination (Papadia et al, 2010). 
Other conditions to exclude are Bilateral Fuch’s Uveitis, Multiple Sclerosis and 
Masquerade syndromes. 
 
Diagnostic criteria for ocular sarcoidois 
1.  Biopsy supported diagnosis with compatible uveitis – Definite Ocular Sarcoidosis 
2.  No Biopsy. Bilateral Hilar Lymphadenopathy (BHL) present with compatible 
uveitis– Presumed Ocular Sarcoidosis 
3.  No Biopsy, BHL neg. Presence of 3 suggestive intraocular signs and two positive 
investigational tests. – Probable Ocular Sarcoidosis 
4.  Biopsy negative. 4 of the suggestive intraocular signs and two positive 
investigational tests    - Possible Ocular Sarcoidosis (Papadia et al, 2010) 
 
Patient example 
One patient that I have been involved with had flu like symptoms five months prior to 
presenting with a bilateral uveitis and on chest X-Ray he definitely had bilateral Hilar 
lymphadenopathy and therefore pulmonary involvement.  Ocular symptoms may 
occur at different times to respiratory symptoms 
These can be generic type symptoms and may only be suspect for sarcoidosis if 
there are other sites involved or the presence on X ray of bilateral Hilar 
lymphadenopathy. 
It has been interesting to note that many patients presenting with ocular sarcoid have 
had raised rashes over tattoos that on biopsy are positive for granulomatous 
inflammation. This is due to the infiltration of sarcoid granulomas in pre existing scar 
tissue (Lodha et al, 2009). 
 
 
Treatment 
The treatment of ocular sarcoidosis can be long and complicated and often involves 
administration of long-term steroids.  Some of the treatments for ocular sarcoidosis 
are also used to treat other organ sites of the disease. 
Anterior uveitis is treated with topical Pred Forte initially intensively and then are 
reducing taper which  can be a long process.  Many patients will have a rebound 
inflammation when steroids are stopped and therefore a regime must be found 
where they remain on maintenance topical steroids at the lowest daily rate that 
controls the inflammation with no rebound of inflammation.  Oral prednisone is used 
for disease not controlled by topical medication or involving posterior segment and 
this is usually1 mg per kg of body weight initially and then slowly tapered to control 
the inflammation.  However, long term steroid use can lead to ocular side effects 
such as ocular hypertension requiring an ocular anti-hypertensive and systemic 
effects such as steroid induced psychosis, sleeplessness, weight gain, moon face 
and bone density issues.   These can be distressing for the patient as the treatment 
may appear to cause them more problems than the disease and continuing 
education and support is required by this group of patients 
Sometimes it is necessary to look at alternative methods of delivering treatment such 
as intravitreal or orbital floor Triamcinalone to manage the ocular symptoms, 
particularly for patients with cystoid macular oedema and vitritis. There is  an 
increased rate of adverse events associated with  such treatment such as raised IOP 
and cataract formation but the systemic complications of long term steroid use are 
negated.  Unfortunately the treatment is short acting and may require repeat 
injections to manage ongoing symptoms (Sallam, Taylor & Lightman, 2011) 
Newer therapies 
Cytotoxic Agents 
Some of the newer forms of treatment of ‘steroid sparing’ immunosuppressants as 
detailed below have been shown to work in ocular sarcoid. These drugs act as 
adjutants to steroids, suppressing the immune system more effectively than steroids 
on their own, and the steroid dose can therefore be reduced. 
Methotrexate and Azathioprine are second line agents that have been widely used in 
the treatment in chronic sarcoidosis whilst Cyclophosamide is used in refractory 
sarcoidois.  These are all cytotoxic drugs but are used long term with the aim of 
significantly reducing the amount of prednisone required and studies show that after 
6 months the dosage of prednisone required to control the disease is decreased 
significantly (Abril & Cohen, 2003). 
Mycophenolate mofetil (MMF) is an antiproliferative drug used in immune mediated 
disorders such as sarcoidosis and has been shown to reduce the severity of the 
inflammation, the amount of steroids required and the frequency of recurrences with 
an improved visual outcome (Jap & Chee, 2008).However these medications a 
gradual increase in dosage levels until therapeutic levels reached.  The patients then 
require regular liver function and renal function tests to ensure continued safety for 
use. 
Cytokine Modulators 
The knowledge that human tumour necrosis factor (TNF) is critical in the genesis 
and maintenance of granulomatous inflammation and therefore is thought to play a 
part in the pathogenesis of sarcoidosis has led to the use of new treatments.  
Infliximab is an monoclonal antibody against TNF.   (Baughman & Lower 2007). It 
may be effective in refractory ocular sarcoid when other treatments have failed 
(Baughman,2002). 
Infliximab is expensive ($NZ1227.00 per dose with minimum of 3 initial doses) and  
has been funded at our District Health Board in only a few patients per year due to 
cost. Ocular sarcoid is only one of the forms of uveitis that benefits with Infliximab. 
Conclusion 
Certainly ocular sarcoid is complicated and requires long term management by 
consultant ophthalmologists with many patients also seeing other medical specialists 
with some seen in a combined ophthalmology/immunology clinic. 
It is a disease that has long term implications for patients health, their well being and 
potentially their sight.  It is important when a patient presents with a possible sarcoid 
related uveitis that a systems approach to examination is used to identify potential 
systemic sites as patients often require care from a multidisciplinary team long term. 
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Key Points 
• Sarcoidosis has both systemic and ocular manifestations. 
• Sarcoidosis can affect the central nervous system, eyes, lungs, skin, 
lymph gland, heart lungs, kidneys. 
• Ocular sarcoid can affect both anterior and posterior segments. 
• Treatment of ocular sarcoid can be topical but often systemic is 
needed to reduce inflammation and risk of permanent visual loss 
from complications. 
 
 
